Royal Bank of Canada Reiterates Outperform Rating for Allogene Therapeutics (NASDAQ:ALLO)
Royal Bank of Canada reaffirmed their outperform rating on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a research note published on Friday,Benzinga reports. Royal Bank of Canada currently has a $10.00 price target on the stock. Several other research analysts have also recently issued reports on ALLO. Canaccord Genuity Group reissued a “buy” […]
Royal Bank of Canada reaffirmed their outperform rating on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a research note published on Friday,Benzinga reports. Royal Bank of Canada currently has a $10.00 price target on the stock. Several other research analysts have also recently issued reports on ALLO. Canaccord Genuity Group reissued a “buy” […]
